Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
BACKGROUND A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (...
Gespeichert in:
| Veröffentlicht in: | Cancer 2014-01, Vol.120 (2), p.229-237 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 237 |
|---|---|
| container_issue | 2 |
| container_start_page | 229 |
| container_title | Cancer |
| container_volume | 120 |
| creator | Tsuchiya, Kaoru Asahina, Yasuhiro Matsuda, Shuya Muraoka, Masaru Nakata, Toru Suzuki, Yuichiro Tamaki, Nobuharu Yasui, Yutaka Suzuki, Shoko Hosokawa, Takanori Nishimura, Takashi Ueda, Ken Kuzuya, Teiji Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Kurosaki, Masayuki Enomoto, Nobuyuki Izumi, Namiki |
| description | BACKGROUND
A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC.
METHODS
Plasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a “VEGF decrease.” An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter.
RESULTS
Patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α‐fetoprotein response (n = 6) survived during the observation period (median, 19.7 months; range, 6.5‐31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1‐year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival.
CONCLUSIONS
A plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC. Cancer 2014;120:229–237. © 2013 American Cancer Society.
Vascular endothelial growth factor (VEGF) is one of the most important targets of sorafenib. Serial changes in plasma VEGF concentrations during sorafenib treatment are dynamic, and a decrease in plasma VEGF 8 weeks after starting sorafenib is a useful predictor of favorable overall survival in patients with advanced hepatocellular carcinoma. |
| doi_str_mv | 10.1002/cncr.28384 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4209122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR28384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5164-ddf1efce268ba66165765bf91e55590d62e139254587ee0a1210c15af849c2953</originalsourceid><addsrcrecordid>eNp9kdFqFDEUhoNY7LZ64wNIbrwRpk0yk9mZG0EGrUKpIArehbOZk51oJhmS2Vn6Mj6r2W6t9UY4EA75zv9zzk_IS84uOGPiUnsdL0RTNtUTsuKsXReMV-IpWTHGmkJW5fdTcpbSj9yuhSyfkVNRcSFyrcivbgC_xUStp5ODNAJdIOmdg0jR92Ee0FlwdBvDfh6oAT2HSGGmDd0j_kwUzIyRphDBoLcbCv1ovU1zhNkGTyHRKWJvD2OJBkPTLi52yYrmoNMv4DX2dMAJ5qDRuTtnDVFbH0Z4Tk4MuIQv7t9z8u3D-6_dx-L689Wn7t11oSWvq6LvDUejUdTNBuqa13Jdy41pOUopW9bXAnnZClnJZo3IgAvONJdgmqrVopXlOXl71J12mxF7jT4v4NQU7QjxVgWw6t8fbwe1DYuqBGvzIbPAm6OAjiGliOZhljN1SEkdUlJ3KWX41WO3B_RPLBl4fQ_kLMCZmK9k01-uEWWbl8wcP3J76_D2P5aqu-m-HM1_A3nSr0g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Tsuchiya, Kaoru ; Asahina, Yasuhiro ; Matsuda, Shuya ; Muraoka, Masaru ; Nakata, Toru ; Suzuki, Yuichiro ; Tamaki, Nobuharu ; Yasui, Yutaka ; Suzuki, Shoko ; Hosokawa, Takanori ; Nishimura, Takashi ; Ueda, Ken ; Kuzuya, Teiji ; Nakanishi, Hiroyuki ; Itakura, Jun ; Takahashi, Yuka ; Kurosaki, Masayuki ; Enomoto, Nobuyuki ; Izumi, Namiki</creator><creatorcontrib>Tsuchiya, Kaoru ; Asahina, Yasuhiro ; Matsuda, Shuya ; Muraoka, Masaru ; Nakata, Toru ; Suzuki, Yuichiro ; Tamaki, Nobuharu ; Yasui, Yutaka ; Suzuki, Shoko ; Hosokawa, Takanori ; Nishimura, Takashi ; Ueda, Ken ; Kuzuya, Teiji ; Nakanishi, Hiroyuki ; Itakura, Jun ; Takahashi, Yuka ; Kurosaki, Masayuki ; Enomoto, Nobuyuki ; Izumi, Namiki</creatorcontrib><description>BACKGROUND
A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC.
METHODS
Plasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a “VEGF decrease.” An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter.
RESULTS
Patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α‐fetoprotein response (n = 6) survived during the observation period (median, 19.7 months; range, 6.5‐31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1‐year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival.
CONCLUSIONS
A plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC. Cancer 2014;120:229–237. © 2013 American Cancer Society.
Vascular endothelial growth factor (VEGF) is one of the most important targets of sorafenib. Serial changes in plasma VEGF concentrations during sorafenib treatment are dynamic, and a decrease in plasma VEGF 8 weeks after starting sorafenib is a useful predictor of favorable overall survival in patients with advanced hepatocellular carcinoma.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.28384</identifier><identifier>PMID: 24122122</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken, NJ: Wiley-Blackwell</publisher><subject>Adult ; Aged ; Aged, 80 and over ; alpha-Fetoproteins - analysis ; antiangiogenic therapy ; Biological and medical sciences ; biomarker ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - mortality ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; hepatocellular carcinoma ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Liver Neoplasms - mortality ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Multivariate Analysis ; Niacinamide - adverse effects ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Original ; Phenylurea Compounds - adverse effects ; Phenylurea Compounds - therapeutic use ; Predictive Value of Tests ; Prognosis ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Treatment Outcome ; Tumors ; Vascular Endothelial Growth Factor A - blood ; α‐fetoprotein</subject><ispartof>Cancer, 2014-01, Vol.120 (2), p.229-237</ispartof><rights>2013 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.</rights><rights>2015 INIST-CNRS</rights><rights>2013 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5164-ddf1efce268ba66165765bf91e55590d62e139254587ee0a1210c15af849c2953</citedby><cites>FETCH-LOGICAL-c5164-ddf1efce268ba66165765bf91e55590d62e139254587ee0a1210c15af849c2953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.28384$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.28384$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28239165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24122122$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsuchiya, Kaoru</creatorcontrib><creatorcontrib>Asahina, Yasuhiro</creatorcontrib><creatorcontrib>Matsuda, Shuya</creatorcontrib><creatorcontrib>Muraoka, Masaru</creatorcontrib><creatorcontrib>Nakata, Toru</creatorcontrib><creatorcontrib>Suzuki, Yuichiro</creatorcontrib><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Yasui, Yutaka</creatorcontrib><creatorcontrib>Suzuki, Shoko</creatorcontrib><creatorcontrib>Hosokawa, Takanori</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Ueda, Ken</creatorcontrib><creatorcontrib>Kuzuya, Teiji</creatorcontrib><creatorcontrib>Nakanishi, Hiroyuki</creatorcontrib><creatorcontrib>Itakura, Jun</creatorcontrib><creatorcontrib>Takahashi, Yuka</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Enomoto, Nobuyuki</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><title>Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC.
METHODS
Plasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a “VEGF decrease.” An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter.
RESULTS
Patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α‐fetoprotein response (n = 6) survived during the observation period (median, 19.7 months; range, 6.5‐31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1‐year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival.
CONCLUSIONS
A plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC. Cancer 2014;120:229–237. © 2013 American Cancer Society.
Vascular endothelial growth factor (VEGF) is one of the most important targets of sorafenib. Serial changes in plasma VEGF concentrations during sorafenib treatment are dynamic, and a decrease in plasma VEGF 8 weeks after starting sorafenib is a useful predictor of favorable overall survival in patients with advanced hepatocellular carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>alpha-Fetoproteins - analysis</subject><subject>antiangiogenic therapy</subject><subject>Biological and medical sciences</subject><subject>biomarker</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Multivariate Analysis</subject><subject>Niacinamide - adverse effects</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Original</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>α‐fetoprotein</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp9kdFqFDEUhoNY7LZ64wNIbrwRpk0yk9mZG0EGrUKpIArehbOZk51oJhmS2Vn6Mj6r2W6t9UY4EA75zv9zzk_IS84uOGPiUnsdL0RTNtUTsuKsXReMV-IpWTHGmkJW5fdTcpbSj9yuhSyfkVNRcSFyrcivbgC_xUStp5ODNAJdIOmdg0jR92Ee0FlwdBvDfh6oAT2HSGGmDd0j_kwUzIyRphDBoLcbCv1ovU1zhNkGTyHRKWJvD2OJBkPTLi52yYrmoNMv4DX2dMAJ5qDRuTtnDVFbH0Z4Tk4MuIQv7t9z8u3D-6_dx-L689Wn7t11oSWvq6LvDUejUdTNBuqa13Jdy41pOUopW9bXAnnZClnJZo3IgAvONJdgmqrVopXlOXl71J12mxF7jT4v4NQU7QjxVgWw6t8fbwe1DYuqBGvzIbPAm6OAjiGliOZhljN1SEkdUlJ3KWX41WO3B_RPLBl4fQ_kLMCZmK9k01-uEWWbl8wcP3J76_D2P5aqu-m-HM1_A3nSr0g</recordid><startdate>20140115</startdate><enddate>20140115</enddate><creator>Tsuchiya, Kaoru</creator><creator>Asahina, Yasuhiro</creator><creator>Matsuda, Shuya</creator><creator>Muraoka, Masaru</creator><creator>Nakata, Toru</creator><creator>Suzuki, Yuichiro</creator><creator>Tamaki, Nobuharu</creator><creator>Yasui, Yutaka</creator><creator>Suzuki, Shoko</creator><creator>Hosokawa, Takanori</creator><creator>Nishimura, Takashi</creator><creator>Ueda, Ken</creator><creator>Kuzuya, Teiji</creator><creator>Nakanishi, Hiroyuki</creator><creator>Itakura, Jun</creator><creator>Takahashi, Yuka</creator><creator>Kurosaki, Masayuki</creator><creator>Enomoto, Nobuyuki</creator><creator>Izumi, Namiki</creator><general>Wiley-Blackwell</general><general>BlackWell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140115</creationdate><title>Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma</title><author>Tsuchiya, Kaoru ; Asahina, Yasuhiro ; Matsuda, Shuya ; Muraoka, Masaru ; Nakata, Toru ; Suzuki, Yuichiro ; Tamaki, Nobuharu ; Yasui, Yutaka ; Suzuki, Shoko ; Hosokawa, Takanori ; Nishimura, Takashi ; Ueda, Ken ; Kuzuya, Teiji ; Nakanishi, Hiroyuki ; Itakura, Jun ; Takahashi, Yuka ; Kurosaki, Masayuki ; Enomoto, Nobuyuki ; Izumi, Namiki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5164-ddf1efce268ba66165765bf91e55590d62e139254587ee0a1210c15af849c2953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>alpha-Fetoproteins - analysis</topic><topic>antiangiogenic therapy</topic><topic>Biological and medical sciences</topic><topic>biomarker</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Multivariate Analysis</topic><topic>Niacinamide - adverse effects</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Original</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>α‐fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuchiya, Kaoru</creatorcontrib><creatorcontrib>Asahina, Yasuhiro</creatorcontrib><creatorcontrib>Matsuda, Shuya</creatorcontrib><creatorcontrib>Muraoka, Masaru</creatorcontrib><creatorcontrib>Nakata, Toru</creatorcontrib><creatorcontrib>Suzuki, Yuichiro</creatorcontrib><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Yasui, Yutaka</creatorcontrib><creatorcontrib>Suzuki, Shoko</creatorcontrib><creatorcontrib>Hosokawa, Takanori</creatorcontrib><creatorcontrib>Nishimura, Takashi</creatorcontrib><creatorcontrib>Ueda, Ken</creatorcontrib><creatorcontrib>Kuzuya, Teiji</creatorcontrib><creatorcontrib>Nakanishi, Hiroyuki</creatorcontrib><creatorcontrib>Itakura, Jun</creatorcontrib><creatorcontrib>Takahashi, Yuka</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Enomoto, Nobuyuki</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuchiya, Kaoru</au><au>Asahina, Yasuhiro</au><au>Matsuda, Shuya</au><au>Muraoka, Masaru</au><au>Nakata, Toru</au><au>Suzuki, Yuichiro</au><au>Tamaki, Nobuharu</au><au>Yasui, Yutaka</au><au>Suzuki, Shoko</au><au>Hosokawa, Takanori</au><au>Nishimura, Takashi</au><au>Ueda, Ken</au><au>Kuzuya, Teiji</au><au>Nakanishi, Hiroyuki</au><au>Itakura, Jun</au><au>Takahashi, Yuka</au><au>Kurosaki, Masayuki</au><au>Enomoto, Nobuyuki</au><au>Izumi, Namiki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2014-01-15</date><risdate>2014</risdate><volume>120</volume><issue>2</issue><spage>229</spage><epage>237</epage><pages>229-237</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC.
METHODS
Plasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a “VEGF decrease.” An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter.
RESULTS
Patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α‐fetoprotein response (n = 6) survived during the observation period (median, 19.7 months; range, 6.5‐31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1‐year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival.
CONCLUSIONS
A plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC. Cancer 2014;120:229–237. © 2013 American Cancer Society.
Vascular endothelial growth factor (VEGF) is one of the most important targets of sorafenib. Serial changes in plasma VEGF concentrations during sorafenib treatment are dynamic, and a decrease in plasma VEGF 8 weeks after starting sorafenib is a useful predictor of favorable overall survival in patients with advanced hepatocellular carcinoma.</abstract><cop>Hoboken, NJ</cop><pub>Wiley-Blackwell</pub><pmid>24122122</pmid><doi>10.1002/cncr.28384</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2014-01, Vol.120 (2), p.229-237 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4209122 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over alpha-Fetoproteins - analysis antiangiogenic therapy Biological and medical sciences biomarker Biomarkers, Tumor - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - mortality Female Gastroenterology. Liver. Pancreas. Abdomen hepatocellular carcinoma Humans Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Multivariate Analysis Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Original Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Predictive Value of Tests Prognosis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Treatment Outcome Tumors Vascular Endothelial Growth Factor A - blood α‐fetoprotein |
| title | Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20plasma%20vascular%20endothelial%20growth%20factor%20at%208%20weeks%20after%20sorafenib%20administration%20as%20predictors%20of%20survival%20for%20advanced%20hepatocellular%20carcinoma&rft.jtitle=Cancer&rft.au=Tsuchiya,%20Kaoru&rft.date=2014-01-15&rft.volume=120&rft.issue=2&rft.spage=229&rft.epage=237&rft.pages=229-237&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.28384&rft_dat=%3Cwiley_pubme%3ECNCR28384%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24122122&rfr_iscdi=true |